Alio, a medical technology company reinventing the management of chronic disease, announced it has raised $18 million in the initial close of a Series C financing, bringing the total amount the company has raised to over $50 million. This round includes the conversion of all outstanding convertible notes. The financing was led by the Widjaja Family Investment Office with participation from the company's existing investors, including Chase Field, LLC and Thomas Krebs, former Treasurer of Penumbra, Inc.

Alio is a medical technology company bringing peace of mind to people with chronic conditions through non-invasive, wireless remote patient monitoring. Currently, Alio uses its SmartPatch™ technology to monitor individuals with end stage kidney disease (ESKD) undergoing dialysis. Alio's platform uses artificial intelligence (AI) to analyze data and create actionable insights. These insights enable targeted interventions with the potential for improved health outcomes and reduced hospitalizations. Alio has built a team of seasoned leaders with diverse backgrounds spanning across industries and segments such as medical devices, wearable technology, government relations, commercialization, and reimbursement.